Lallemand finalizes acquisition of Swiss biotech firm 

SWITZERLAND- Industrial biotechnology leader Lallemand has successfully acquired Swiss biotechnology firm Evolva for approximately CHF20 million (around US$23.5 million) through its Swiss affiliate, Danstar Ferment. 

The acquisition, completed after receiving approval from Evolva shareholders at an extraordinary general meeting on December 21, 2023, is expected to fortify Lallemand’s position in the health and flavor sectors.

Lars Asferg, President of Lallemand Bio-Ingredient, expressed excitement about the strategic fit with Evolva’s precision fermentation capabilities, stating, “Evolva offers us a strong strategic fit with our yeast-based technology platform.”

The deal allows Lallemand to leverage Evolva’s proprietary precision fermentation technology and research and development capabilities. Asferg highlighted the potential for expanding Lallemand’s product portfolio, particularly within health ingredients such as Veri-te resveratrol, as well as flavor and fragrance aroma components like Valencene and natural Nootkatone.

“We look forward to welcoming the Evolva employees into our Lallemand family and continuing to work with suppliers, existing and new customers in bringing sustainable, yeast-based ingredients to markets globally via Lallemand’s extensive commercial and operational network,” added Asferg.

Evolva, specializing in natural ingredients derived from yeast for applications in flavors, fragrances, health ingredients, cosmetics, and health protection, faced financial challenges, leading to the strategic acquisition by Lallemand. 

The deal comes after Evolva revoked its performance and projections for 2023 following negotiations with its financing partner, Nice & Green.

Despite securing funding for the remainder of the year and establishing new partnerships, including distribution agreements, Evolva’s Board of Directors recognized that financing challenges made it impossible for the company to continue developing its value potential as an independent stock-listed entity.

“The Board of Directors regrets that, despite substantial operational improvements achieved over the last 20 months under the new management, the financing challenges made it impossible for Evolva to continue to develop its value potential as an independent stock-listed company,” Stephan Schindler, Chairman of Evolva, stated.

Headquartered in Reinach, Basel, Evolva has 48 employees and has been a key player in the research, development, and commercialization of natural yeast-derived ingredients.

This acquisition aligns with Lallemand’s commitment to innovation and sustainability in the biotechnology sector, enhancing its capabilities to deliver cutting-edge solutions to global markets.

For all the latest grains industry news from Africa, the Middle East, and the World, subscribe to our weekly NEWSLETTERS, follow us on LinkedIn, and subscribe to our YouTube channel.